Brief: Forward Pharma says U.S. patent office declares interference between Co and Biogen regarding treatment of multiple sclerosis
April 14 (Reuters) - Forward Pharma A/S FWP.O : * U.S. patent office declares an interference between Forward Pharma and Biogen regarding the treatment of multiple sclerosis * Source text for Eikon ID:nGNXVDGLOa * Further company coverage FWP.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Forward Pharma A/S
See all newsBrief: Forward Pharma- Announces Termination Of Its American Depositary Receipts Facility
U.S. STOCKS ON THE MOVE-Madrigal, Disney, Forward Pharma
Forward Pharma slides to record low on delisting notice from Nasdaq
Brief: Forward Pharma Announces Delisting Its American Depositary Shares From Nasdaq Capital Market
Brief: Forward Pharma A/S Submitted A Request For A Written Decision Regarding Petition For Review Regarding EP2801355 To The EBA